» Articles » PMID: 37056267

Exosome-guided Direct Reprogramming of Tumor-associated Macrophages from Protumorigenic to Antitumorigenic to Fight Cancer

Abstract

Highly immunosuppressive tumor microenvironment containing various protumoral immune cells accelerates malignant transformation and treatment resistance. In particular, tumor-associated macrophages (TAMs), as the predominant infiltrated immune cells in a tumor, play a pivotal role in regulating the immunosuppressive tumor microenvironment. As a potential therapeutic strategy to counteract TAMs, here we explore an exosome-guided direct reprogramming of tumor-supportive M2-polarized TAMs into tumor-attacking M1-type macrophages. Exosomes derived from M1-type macrophages (M1-Exo) promote a phenotypic switch from anti-inflammatory M2-like TAMs toward pro-inflammatory M1-type macrophages with high conversion efficiency. Reprogrammed M1 macrophages possessing protein-expression profiles similar to those of classically activated M1 macrophages display significantly increased phagocytic function and robust cross-presentation ability, potentiating antitumor immunity surrounding the tumor. Strikingly, these M1-Exo also lead to the conversion of human patient-derived TAMs into M1-like macrophages that highly express MHC class II, offering the clinical potential of autologous and allogeneic exosome-guided direct TAM reprogramming for arming macrophages to join the fight against cancer.

Citing Articles

Exosome crosstalk between cancer stem cells and tumor microenvironment: cancer progression and therapeutic strategies.

Li Q, He G, Yu Y, Li X, Peng X, Yang L Stem Cell Res Ther. 2024; 15(1):449.

PMID: 39578849 PMC: 11583673. DOI: 10.1186/s13287-024-04061-z.


Biomimetic nanocarriers in cancer therapy: based on intercellular and cell-tumor microenvironment communication.

Mengyuan H, Aixue L, Yongwei G, Qingqing C, Huanhuan C, Xiaoyan L J Nanobiotechnology. 2024; 22(1):604.

PMID: 39370518 PMC: 11456251. DOI: 10.1186/s12951-024-02835-4.


Tumor-associated exosomes in cancer progression and therapeutic targets.

Liu X, Wu F, Pan W, Liu G, Zhang H, Yan D MedComm (2020). 2024; 5(9):e709.

PMID: 39247621 PMC: 11380050. DOI: 10.1002/mco2.709.


Supramolecular artificial Nano-AUTACs enable tumor-specific metabolism protein degradation for synergistic immunotherapy.

Wang Y, Yang L, Yan C, Du Y, Li T, Yang W Sci Adv. 2024; 10(25):eadn8079.

PMID: 38905336 PMC: 11192078. DOI: 10.1126/sciadv.adn8079.


Tumor Microenvironment Modulation by Cancer-Derived Extracellular Vesicles.

Ten A, Kumeiko V, Farniev V, Gao H, Shevtsov M Cells. 2024; 13(8.

PMID: 38667297 PMC: 11049026. DOI: 10.3390/cells13080682.


References
1.
Sherborne A, Thom M, Paterson S, Jury F, Ollier W, Stockley P . The genetic basis of inbreeding avoidance in house mice. Curr Biol. 2007; 17(23):2061-6. PMC: 2148465. DOI: 10.1016/j.cub.2007.10.041. View

2.
Martinez F, Helming L, Milde R, Varin A, Melgert B, Draijer C . Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood. 2013; 121(9):e57-69. DOI: 10.1182/blood-2012-06-436212. View

3.
Liang Y, Duan L, Lu J, Xia J . Engineering exosomes for targeted drug delivery. Theranostics. 2021; 11(7):3183-3195. PMC: 7847680. DOI: 10.7150/thno.52570. View

4.
Ding J, Lu G, Nie W, Huang L, Zhang Y, Fan W . Self-Activatable Photo-Extracellular Vesicle for Synergistic Trimodal Anticancer Therapy. Adv Mater. 2021; 33(7):e2005562. DOI: 10.1002/adma.202005562. View

5.
Park O, Choi E, Yu G, Kim J, Kang Y, Jung H . Efficient Delivery of Tyrosinase Related Protein-2 (TRP2) Peptides to Lymph Nodes using Serum-Derived Exosomes. Macromol Biosci. 2018; 18(12):e1800301. DOI: 10.1002/mabi.201800301. View